Docosahexaenoic acid-enriched canola oil increases adiponectin concentrations: a randomized crossover controlled intervention trial

Nutr Metab Cardiovasc Dis. 2015 Jan;25(1):52-9. doi: 10.1016/j.numecd.2014.08.003. Epub 2014 Aug 20.

Abstract

Background and aims: Little is known about the effect of various dietary fatty acids on pro- and anti-inflammatory processes. We investigated the effect of 5 oils containing various amounts of alpha-linolenic acid (ALA), linoleic acid (LA), oleic acid (OA) and docosahexaenoic acid (DHA) on plasma inflammatory biomarkers and expression levels of key inflammatory genes and transcription factors in whole blood cells.

Methods and results: In a randomized, crossover controlled nutrition intervention, 114 adult men and women with abdominal obesity and at least one other criterion for the metabolic syndrome consumed 5 experimental isoenergetic diets for 4 weeks each, separated by 4-week washout periods. Each diet provided 60 g/3000 kcal of different oils: 1) control corn/safflower oil blend (CornSaff; LA-rich), 2) flax/safflower oil blend (FlaxSaff; ALA-rich), 3) conventional canola oil (Canola; OA-rich), 4) high oleic canola oil (CanolaOleic; highest OA content), 5) DHA-enriched high oleic canola oil (CanolaDHA; OA- and DHA-rich). Gene expression in whole blood cells was assessed in a subset of 62 subjects. CanolaDHA increased plasma adiponectin concentrations compared with the control CornSaff oil treatment (+4.5%, P = 0.04) and FlaxSaff (+6.9%, P = 0.0008). CanolaDHA also reduced relative expression levels of interleukin (IL)1B compared with CornSaff and Canola (-11% and -13%, respectively, both P = 0.03). High-sensitivity C-reactive protein concentrations were lower after Canola than after FlaxSaff (-17.8%, P = 0.047).

Conclusion: DHA-enriched canola oil exerts anti-inflammatory effects compared with polyunsaturated fatty acids from plant sources.

Trial registration: ClinicalTrials.gov NCT01351012.

Keywords: Adiponectin; Alpha-linolenic acid; C-Reactive protein; Cardiovascular disease; Dietary oils; Docosahexaenoic acid; Inflammation; Interleukin-6.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / agonists*
  • Adiponectin / blood
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / analysis
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Biomarkers / blood
  • Biomarkers / metabolism
  • Blood Cells / immunology
  • Blood Cells / metabolism
  • Body Mass Index
  • Canada / epidemiology
  • Cross-Over Studies
  • Docosahexaenoic Acids / analysis
  • Docosahexaenoic Acids / therapeutic use*
  • Double-Blind Method
  • Fatty Acids, Monounsaturated / chemistry
  • Fatty Acids, Monounsaturated / therapeutic use*
  • Female
  • Food, Fortified
  • Gene Expression Regulation
  • Humans
  • Inflammation Mediators / antagonists & inhibitors*
  • Inflammation Mediators / blood
  • Inflammation Mediators / metabolism
  • Male
  • Metabolic Syndrome / epidemiology
  • Metabolic Syndrome / etiology
  • Metabolic Syndrome / prevention & control*
  • Middle Aged
  • Obesity, Abdominal / diet therapy*
  • Obesity, Abdominal / immunology
  • Obesity, Abdominal / metabolism
  • Obesity, Abdominal / physiopathology
  • Pennsylvania / epidemiology
  • Rapeseed Oil
  • Risk
  • Young Adult

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers
  • Fatty Acids, Monounsaturated
  • Inflammation Mediators
  • Rapeseed Oil
  • Docosahexaenoic Acids

Associated data

  • ClinicalTrials.gov/NCT01351012